Annexin V-CLIO: a nanoparticle for detecting apoptosis by MRI.

Center for Molecular Imaging Research, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129, USA.
Academic Radiology (Impact Factor: 1.75). 09/2002; 9 Suppl 2:S310-1.
Source: PubMed
Download full-text


Available from: Eyk Schellenberger, May 14, 2014
29 Reads
  • Source
    • "Nano-sized magnetic resonance imaging (MRI) contrast agents are used for intraoperative imaging in the context of neuro-oncological interventions [11] [16]. In this scheme, detection in NCC is done using, Gadolinium-based nano-particles [18], Iron oxide-based nano-particles or multiple-mode imaging contrast nano-agents [25] [8] [29] [21] [31] [30]. Moreover, detection over the MCC is accomplished using a combination of MRI and biological targeting [13] or optical detection [16] [13] [5]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: A scheme for detection of abnormality in molecular nano-networks is proposed. This is motivated by the fact that early diagnosis, classification and detection of diseases such as cancer play a crucial role in their successful treatment. The proposed nano-abnormality detection scheme (NADS) comprises of a two-tier network of sensor nano-machines (SNMs) in the first tier and a data gathering node (DGN) at the sink. The SNMs detect the presence of competitor cells as abnormality that is captured by variations in parameters of a nano-communications channel. In the second step, the SNMs transmit micro-scale messages over a noisy micro communications channel (MCC) to the DGN, where a decision is made upon fusing the received signals. The detection performance of each SNM is analyzed by setting up a Neyman-Pearson test. Next, taking into account the effect of the MCC, the overall performance of the proposed NADS is quantified in terms of probabilities of misdetection and false alarm. A design problem is formulated, when the optimized concentration of SNMs in a sample is obtained for a high probability of detection and a limited probability of false alarm.
    Nano Communication Networks 05/2012; 3(4). DOI:10.1016/j.nancom.2012.09.008
  • Source
    • "non-toxicity, biodegradability, biocompatibility) characteristics [1] [2] [3] [4] [5] [6] [7] [8] that empower their prominent application position in diverse fields of medicine. Particles such as cross-linked iron oxide (CLIO) [9] [10], ultrasmall superparamagnetic iron oxide (USPIO) [11] [12] [13], and monocrystalline iron oxide nanoparticles (MIONs) [14] [15] have all been developed as imaging agents in magnetic resonance imaging (MRI). Some of the reported particles are likely to be taken up by macrophages and immune cells and can be used to image lymph nodes and inflammatory tissues. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Superparamagnetic nanoparticles (20-40 nm) of maghemite, γ-Fe(2)O(3), with well-defined stoichiometric structure, are synthesized by the borohydride reduction of ferric chloride at an elevated temperature (100°C) followed by thermal treatment of the reaction product. Prepared maghemite nanoparticles reveal excellent colloidal stability for a long time without the necessity for any additional surface modification. These colloidal features are due to surface stabilizing OH(-) groups, which act as charge barriers preventing a particle aggregation and enabling a reversible binding of various oppositely charged organic substances. Such binding with rhodamine B isothiocyanate results in the fluorescent magnetic nanocarrier providing, at the same time, a spacer arm for covalent immobilization of other biosubstances including enzymes. In this work, we exploit this general applicability of the developed nanocarrier for covalent immobilization of glucose oxidase. This is the first reported example of magnetically drivable fluorescent nanocatalyst. The immobilized enzyme creates a 3-5 nm thick layer on the nanoparticle surface as proved by high-resolution transmission electron microscopy. This layer corresponds to 10 enzyme molecules, which are bound to the nanoparticle surface as found by the fluorimetric determination of flavin adenine dinucleotide. The developed magnetic fluorescent nanocatalyst, showing a rate constant of 32.7s(-1) toward glucose oxidation, can be used as a biosensor in various biochemical, biotechnological, and food chemistry applications. The presence of the nanocatalyst can be simply monitored by its fluorescence; moreover, it can be easily separated from the solution by an external magnetic field and repeatedly used without a loss of catalytic efficiency.
    Acta biomaterialia 02/2012; 8(6):2068-76. DOI:10.1016/j.actbio.2012.02.005 · 6.03 Impact Factor
  • Source
    • "These agents have been used extensively for preclinical work and commercial preparations have been used in clinical trials. CLIO particles represent a stabilized dextran-coated iron oxide nanoparticle preparation specifically designed for targeting [13] [17] [18]. In these particles , the iron oxide core is caged by the cross-linked dextran coating so that there exists no equilibrium between free and iron oxide-associated dextran moieties. "
    [Show abstract] [Hide abstract]
    ABSTRACT: A novel polyacrylamide superparamagnetic iron oxide nanoparticle platform is described which has been synthetically prepared such that multiple crystals of iron oxide are encapsulated within a single polyacrylamide matrix (PolyAcrylamide Magnetic [PAM] nanoparticles). This formulation provides for an extremely large T2 and T2* relaxivity of between 620 and 1140 sec(-1) mM(-1). Administration of PAM nanoparticles into rats bearing orthotopic 9L gliomas allowed quantitative pharmacokinetic analysis of the uptake of nanoparticles in the vasculature, brain, and glioma. Addition of polyethylene glycol of varying sizes (0.6, 2, and 10 kDa) to the surface of the PAM nanoparticles resulted in an increase in plasma half-life and affected tumor uptake and retention of the nanoparticles as quantified by changes in tissue contrast using MRI. The flexible formulation of these nanoparticles suggests that future modifications could be accomplished allowing for their use as a targeted molecular imaging contrast agent and/or therapeutic platform for multiple indications.
    Molecular Imaging 11/2003; 2(4):324-32. DOI:10.1162/153535003322750664 · 1.96 Impact Factor
Show more